These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19. Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045 [TBL] [Abstract][Full Text] [Related]
10. Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function. Padín JF; Pérez-Ortiz JM; Redondo-Calvo FJ Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062796 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo. Song EJ; Españo E; Shim SM; Nam JH; Kim J; Lee K; Park SK; Lee CK; Kim JK Sci Rep; 2021 May; 11(1):9427. PubMed ID: 33941825 [TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D Cells; 2021 Jul; 10(7):. PubMed ID: 34359926 [TBL] [Abstract][Full Text] [Related]
14. Favipiravir in SARS-CoV-2 Infection: Is it Worth it? Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987 [TBL] [Abstract][Full Text] [Related]
15. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
16. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
17. Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses. Chianese A; Zannella C; Monti A; Doti N; Sanna G; Manzin A; De Filippis A; Galdiero M Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762191 [TBL] [Abstract][Full Text] [Related]
18. Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. Bai X; Hippensteel J; Leavitt A; Maloney JP; Beckham D; Garcia C; Li Q; Freed BM; Ordway D; Sandhaus RA; Chan ED Med Hypotheses; 2021 Jan; 146():110394. PubMed ID: 33239231 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of effects of aprotinin and tranexamic acid on blood loss in heart surgery]. Corbeau JJ; Monrigal JP; Jacob JP; Cottineau C; Moreau X; Bukowski JG; Subayi JB; Delhumeau A Ann Fr Anesth Reanim; 1995; 14(2):154-61. PubMed ID: 7486272 [TBL] [Abstract][Full Text] [Related]
20. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]